Patents by Inventor Brian Zeglis

Brian Zeglis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220040337
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 10, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Brian ZEGLIS, Jason LEWIS, Thomas REINER, Jacob Lee HOUGHTON, Jan-Philip MEYER, Christian BRAND
  • Publication number: 20220024904
    Abstract: A label that permits rebridging of disulfide linkages in antibodies or proteins. The label has a general formula given by wherein R1 is methyl, ethyl or propyl and R2 is a metal chelator, a fluorophore or a click-chemistry synthon.
    Type: Application
    Filed: July 6, 2021
    Publication date: January 27, 2022
    Inventors: Brian Zeglis, Guillaume Dewaele-Le Roi, Eric W. Price, Elaheh Khozeimeh Sarbisheh
  • Publication number: 20210353784
    Abstract: Peptide formulations of a general formula of X-mtp53ODP, where mtp53ODP is a peptide that binds to tetrameric mp53 tetramers in vivo. X is a detection agent, such a fluorophore or radioligand, and/or a DNA-damaging agent. The primary structures of suitable mtp53ODPs are given as SEQ ID NOS: 1-8.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 18, 2021
    Inventors: Jill Bargonetti-Chavarria, Gu Xiao, Brian Zeglis, George Annor, Kimberly Fung
  • Patent number: 11135320
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: October 5, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Brian Zeglis, Jason Lewis, Thomas Reiner, Jacob Lee Houghton, Jan-Philip Meyer, Christian Brand
  • Patent number: 11000604
    Abstract: A label for an antibody or protein is described that is both site-selective and unusually stable in vivo. The label has a general formula given by Formula (I) wherein R1 is a metal chelator, a fluorophore or a click-chemistry synthon.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: May 11, 2021
    Assignee: Research Foundation of the City University of New York
    Inventors: Brian Zeglis, Pierre Adumeau, Maria Davydova
  • Publication number: 20200397928
    Abstract: A label for an antibody or protein is described that is both site-selective and unusually stable in vivo. The label has a general formula given by Formula (I) wherein R1 is a metal chelator, a fluorophore or a click-chemistry synthon.
    Type: Application
    Filed: May 17, 2018
    Publication date: December 24, 2020
    Inventors: Brian Zeglis, Pierre Adumeau, Maria Davydova
  • Publication number: 20190091351
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Application
    Filed: November 28, 2018
    Publication date: March 28, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Brian ZEGLIS, Jason LEWIS, Thomas REINER, Jacob Lee HOUGHTON, Jan-Philip MEYER, Christian BRAND
  • Publication number: 20160331852
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Application
    Filed: August 14, 2015
    Publication date: November 17, 2016
    Inventors: Brian Zeglis, Jason Lewis, Thomas Reiner, Jacob Lee Houghton, Jan-Philip Meyer
  • Publication number: 20150359913
    Abstract: This invention is in the field of labeled peptide construction for medical treatment and analysis. The invention relates to synthetic labeled peptide compositions, methods of synthesis, and methods of use for the synthetic labeled peptide compositions for medical treatment, imaging, and research purposes.
    Type: Application
    Filed: January 24, 2014
    Publication date: December 17, 2015
    Inventors: Thomas Reiner, Jason Stuart Lewis, Ralph Weissleder, Brian Zeglis
  • Patent number: 7786298
    Abstract: In accordance with the present invention there are provided sterically demanding intercalators. These compounds are useful for detection of a base-pair mismatch, such as by measuring fluorescence of complexes formed by the compounds of the invention and nucleic acid duplexes. The compounds are also capable of catalyzing photolytic cleavage of nucleic acids.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: August 31, 2010
    Assignee: California Institute of Technology
    Inventors: Jacqueline K. Barton, Brian Zeglis, Irvin H. Lau, Jonathan Hart, Mi Hee Lim
  • Publication number: 20070224612
    Abstract: In accordance with the present invention there are provided sterically demanding intercalators. These compounds are useful for detection of a base-pair mismatch, such as by measuring fluorescence of complexes formed by the compounds of the invention and nucleic acid duplexes. The compounds are also capable of catalyzing photolytic cleavage of nucleic acids.
    Type: Application
    Filed: January 12, 2007
    Publication date: September 27, 2007
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Jacqueline Barton, Brian Zeglis, Irvin Lau, Jonathan Hart, Mi Lim